The Fort Worth Press - Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024

USD -
AED 3.672498
AFN 64.999798
ALL 82.324126
AMD 360.439737
ANG 1.790403
AOA 917.999825
ARS 1543.774978
AUD 1.480635
AWG 1.8
AZN 1.699363
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.686902
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42842
CDF 2315.00023
CHF 0.840095
CLF 0.025417
CLP 1000.480332
CNY 6.67175
CNH 6.66782
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.18975
DJF 178.554905
DKK 6.790305
DOP 60.996961
DZD 137.014347
EGP 53.649023
ERN 15
ETB 164.576405
EUR 0.90831
FJD 2.280098
FKP 0.756558
GBP 0.75785
GEL 2.590074
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 74.000006
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84665
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.23032
IDR 18267.95
ILS 3.22225
IMP 0.756558
INR 93.92255
IQD 1520.102326
IRR 1913737.523681
ISK 124.069717
JEP 0.756558
JMD 158.434973
JOD 0.70902
JPY 159.523499
KES 130.039569
KGS 87.449397
KHR 4119.418691
KMF 447.000366
KPW 900.00035
KRW 1335.070061
KWD 0.31151
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.90096
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809885
MVR 15.396662
MWK 1738.739965
MXN 18.573803
MYR 4.093898
MZN 63.899938
NAD 16.951268
NGN 1347.489819
NIO 36.903315
NOK 9.600095
NPR 151.114437
NZD 1.81263
OMR 0.384508
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.963967
PKR 277.274459
PLN 4.00014
PYG 6223.068898
QAR 3.655265
RON 4.859302
RSD 106.818993
RUB 82.553706
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.770647
SDG 601.516238
SEK 10.079445
SGD 1.2891
SHP 0.752984
SLE 23.050274
SLL 20969.503664
SOS 573.051087
SRD 37.49018
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.901027
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392297
TTD 6.806306
TWD 32.943501
TZS 2651.477006
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 595.812425
XAG 0.021002
XAU 0.000258521515
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.812425
XPF 108.186074
YER 236.549829
ZAR 16.951101
ZMK 9001.197322
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084233
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024

Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024

HILLSIDE, NJ / ACCESS Newswire / February 13, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2024.

Text size:

Revenue for the quarter ended December 31, 2024 was $12.6 million compared to $11.5 million for the quarter ended December 31, 2023, an increase of $1.1 million or 9.6%. The Company had operating income in the quarter ended December 31, 2024 of approximately $0.2 million compared to an operating loss in the quarter ended December 31, 2023, of approximately $0.5 million.

Revenue for the six-month period ended December 31, 2024 was $26.2 million compared to $24.4 million for the six-month period ended December 31, 2023, an increase of $1.8 million or 7.4%. The Company had operating income for the six-month period ended December 31, 2024 of approximately $0.7 million and an operating loss of approximately $0.5 million for the six-month period ended December 31, 2023.

For the quarters ended December 31, 2024 and 2023, the Company had net income of $0.1 million and a net loss of approximately $0.5 million, respectively. The Company's net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the quarters ended December 31, 2024 and 2023 were $0.00 and $(0.01) per share of common stock, respectively.

For the six-month periods ended December 31, 2024 and 2023, the Company had net income of $0.4 million and a net loss of approximately $0.4 million, respectively. The Company's net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the six months ended December 31, 2024 and 2023 were $0.01 and $(0.02) per share of common stock, respectively.

"Our revenues increased by 7.4% in the six months ended December 31, 2024 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 82% and 90% of total revenue in the six-month period ended December 31, 2024 and 2023, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue," the Co-CEOs further stated.

A summary of our financial results for the three months and six months ended December 31, 2024 and 2023 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)

Three Months Ended

Six Months Ended

December 31,

December 31,

2024

2023

2024

2023

Total revenue

$

12,614

$

11,509

$

26,231

$

24,424

Cost of sales

11,443

10,989

23,689

23,072

Gross profit

1,171

520

2,542

1,352

Selling and administrative expenses

969

972

1,850

1,858

Operating income (loss)

202

(452

)

692

(506

)

Other income (expense), net

(17

)

-

(3

)

8

Income (loss) before income taxes

185

(452

)

689

(498

)

Income tax expense (benefit), net

69

(70

)

314

(57

)

Net income (loss)

$

116

$

(382

)

$

375

$

(441

)

Net income (loss) per share:
Basic

$

0.00

$

(0.01

)

$

0.01

$

(0.02

)

Diluted

$

0.00

$

(0.01

)

$

0.01

$

(0.02

)

Weighted average common shares outstanding:
Basic

30,174,664

30,099,610

30,137,137

30,032,762

Diluted

31,303,011

30,099,610

30,810,401

30,032,762

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and the tightened labor markets; the impact of the war in Ukraine; the impact of the Israel-Hamas war; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact:

Dina Masi, CFO
Integrated BioPharma, Inc.
[email protected]
888.319.6962

SOURCE: Integrated BioPharma, Inc.



View the original press release on ACCESS Newswire

T.Gilbert--TFWP